参芪扶正注射液对肺癌化疗患者癌症相关疲劳的干预作用

目的：探析参芪扶正注射液对晚期非小细胞肺癌（NSCLC）患者癌症相关疲劳（CRF）的干预效果。方法：选取2012年4月-2014年3月本院肿瘤治疗中心收治的97例晚期非小细胞肺癌患者,按照随机数字表法将其分为观察组49例和对照组48例,观察组给予参芪扶正注射液联合吉西他滨＋顺铂（GP）方案治疗,对照组予以GP方案化疗。治疗2周期后,观察比较两组患者治疗前后癌症相关疲劳的情况、评价生活质量（QOL）及肿瘤近期疗效。结果：两组治疗后中重度疲劳阳性率均明显低于治疗前,且观察组治疗后中重度疲劳阳性率26.53%明显低于对照组的45.83%,生活质量改善有效率87.76%明显高于对照组的70.83%,客观缓解率53.10%明显高于对照组的33.33%,差异均有统计学意义（P〈0.05）。结论：参芪扶正注射液联合GP方案化疗可有效减轻患者的癌症相关疲劳,提高患者的生活质量和肿瘤治疗有效率,值得临床推广。

Intervention Effect of Shenqi Fuzheng Injection on Cancer-related Fatigue in the Patients with Non-Small Cell Lung Cancer during Chemotherapy

Objective：To explore the intervention effect of Shenqi Fuzheng injection on cancer-related fatigue（CRF） in the patients with non-small cell lung carcinoma（NSCLC） during chemotherapy.Method：97 patients with NSCLC in our tumor treatment center from April 2012 to March 2014 were selected,they were divided into the observation group for 49 cases and the control group for 48 cases according to the random number table method.The observation group was treated with GP chemotherapy combined with Shenqi Fuzheng injection and the control group was treated with GP chemotherapy.After 2 cycles of chemotherapy the CRF,cancer-related fatigue before and after treatment of the two groups were observed and compared,quality of life（QOL） and recent effect of tumor were evaluated.Result：The positive rate of moderate to severe fatigue of two groups after treatment were significantly lower than those of before treatment,and the positive rate of moderate to severe fatigue in observation group after treatment was 26.53%,it was significantly lower than 45.83% in control group,the QOL of observation group was 87.76%,it was significantly higher than 70.83% of control group,the objective response rate（RR） of observation group was 53.10%,it was significantly higher than 33.33% of control group,the differences were statistically significant（P〈0.05）.Conclusion：Shenqi Fuzheng injection combined GP chemotherapy can relieve the CRF and improve the QOL and short-term effect rate for NSCLC patients,is worthy of clinical promotion.